The Herald of Everett, Washington
HeraldNet on Facebook HeraldNet on Twitter HeraldNet RSS feeds HeraldNet Pinterest HeraldNet Google Plus HeraldNet Youtube
HeraldNet Newsletters  Newsletters: Sign up | Manage  Green editions icon Green editions

Calendar


HeraldNet Headlines
HeraldNet Newsletter Delivered to your inbox each week.
Published: Thursday, November 8, 2012, 12:01 a.m.

Statins may lower cancer death risk

LOS ANGELES -- If you take statins to lower your cholesterol, you may also be lowering your risk of death from cancer, new research suggests.
A report being published in today's edition of the New England Journal of Medicine is one of a number of recent papers suggesting that statins not only limit the growth of cancer cells but also make them more vulnerable to certain therapies.
"Regular statin use before and after a diagnosis of cancer could theoretically reduce cancer-related mortality," wrote study leader Sune Nielsen, a biochemist at the University of Copenhagen who based his findings on an analysis of more than 5.5 million people in Denmark.
Statins are already used by millions of Americans to improve their cardiovascular health by reducing the liver's production of cholesterol. Though an excessive amount of cholesterol can inhibit blood flow by narrowing or blocking arteries, the waxy substance is actually necessary for good health.
Among other functions, cholesterol helps to build and maintain cell membranes, and is essential to their proliferation. Therefore, when cholesterol production is limited, the ability of cancer cells to reproduce uncontrollably is diminished, scientists say. There has also been some experimental evidence that statins may increase the effectiveness of radiation therapy.
Nielsen and his colleagues based their conclusions on an analysis of government death records and other medical data for the entire population of Denmark between 1995 and 2007. The Danish Cancer Registry tracks 98 percent of all diagnosed cancer cases, and the Danish Register of Medicinal Products Statistics keeps track of all drugs dispensed in the country, including statins. Information on race, gender, education and place of residence was obtained through other public records.
The researchers zeroed in on cancer patients who were 40 or older, on the assumption that younger people were unlikely to take statins. That left a total of 295,925 cancer patients, including 18,721 who used statins.
Nielsen and his colleagues found that patients who took statins were 15 percent less likely to die during the course of the study - of cancer or any other cause - than those who hadn't taken the cholesterol-lowering medication. But the researchers didn't find a clear relationship between the size of the statin dose and the patient's risk of death, which suggested that "any statin dose will suffice in reducing mortality among patients with cancer."
The National Cancer Institute is wrapping up a clinical trial in the U.S. examining whether statins can help treat melanoma. However, the organization has warned patients not to take statins for cancer prevention unless they are participating in a clinical trial.
The authors of the Danish study noted several limitations in their analysis, the most significant being that 97 percent of the patients were whites of Danish descent. "Our results may not necessarily apply to other ethnic groups," they wrote.
They also said it was possible that statin use was a marker for increased health awareness among patients, which could affect the results.

Share your comments: Log in using your HeraldNet account or your Facebook, Twitter or Disqus profile. Comments that violate the rules are subject to removal. Please see our terms of use. Please note that you must verify your email address for your comments to appear.

You are logged in using your HeraldNet ID. Click here to update your profile. | Log out.

Our new comment system is not supported in IE 7. Please upgrade your browser here.

comments powered by Disqus
digital subscription promo

Subscribe now

Unlimited digital access starting at 99 cents, or included with any print subscription.

loading...